1
|
Ray KM. Interval Cancers in Understanding Screening Outcomes. Radiol Clin North Am 2024; 62:559-569. [PMID: 38777533 DOI: 10.1016/j.rcl.2023.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2024]
Abstract
Interval breast cancers are not detected at routine screening and are diagnosed in the interval between screening examinations. A variety of factors contribute to interval cancers, including patient and tumor characteristics as well as the screening technique and frequency. The interval cancer rate is an important metric by which the effectiveness of screening may be assessed and may serve as a surrogate for mortality benefit.
Collapse
Affiliation(s)
- Kimberly M Ray
- Department of Radiology and Biomedical Sciences, University of California, San Francisco, UCSF Medical Center, 1825 4th Street, L3185, Box 4034, San Francisco, CA 94107, USA.
| |
Collapse
|
2
|
Aspberg J, Heijl A, Bengtsson B. Estimating the Length of the Preclinical Detectable Phase for Open-Angle Glaucoma. JAMA Ophthalmol 2023; 141:48-54. [PMID: 36416831 PMCID: PMC9857634 DOI: 10.1001/jamaophthalmol.2022.5056] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Accepted: 10/09/2022] [Indexed: 11/24/2022]
Abstract
Importance A 50% reduction of glaucoma-related blindness has previously been demonstrated in a population that was screened for open-angle glaucoma. Ongoing screening trials of high-risk populations and forthcoming low-cost screening methods suggest that such screening may become more common in the future. One would then need to estimate a key component of the natural history of chronic disease, the mean preclinical detectable phase (PCDP). Knowledge of the PCDP is essential for the planning and early evaluation of screening programs and has been estimated for several types of cancer that are screened for. Objective To estimate the mean PCDP for open-angle glaucoma. Design, Setting, and Participants A large population-based screening for open-angle glaucoma was conducted from October 1992 to January 1997 in Malmö, Sweden, including 32 918 participants aged 57 to 77 years. A retrospective medical record review was conducted to assess the prevalence of newly detected cases at the screening, incidence of new cases after the screening, and the expected clinical incidence, ie, the number of new glaucoma cases expected to be detected without a screening. The latter was derived from incident cases in the screened age cohorts before the screening started and from older cohorts not invited to the screening. A total of 2029 patients were included in the current study. Data were analyzed from March 2020 to October 2021. Main Outcomes and Measures The length of the mean PCDP was calculated by 2 different methods: first, by dividing the prevalence of screen-detected glaucoma with the clinical incidence, assuming that the screening sensitivity was 100% and second, by using a Markov chain Monte Carlo (MCMC) model simulation that simultaneously derived both the length of the mean PCDP and the sensitivity of the screening. Results Of 2029 included patients, 1352 (66.6%) were female. Of 1420 screened patients, the mean age at screening was 67.4 years (95% CI, 67.2-67.7). The mean length of the PCDP of the whole study population was 10.7 years (95% CI, 8.7-13.0) by the prevalence/incidence method and 10.1 years (95% credible interval, 8.9-11.2) by the MCMC method. Conclusions and Relevance The mean PCDP was similar for both methods of analysis, approximately 10 years. A mean PCDP of 10 years found in the current study allows for screening with reasonably long intervals, eg, 5 years.
Collapse
Affiliation(s)
- Johan Aspberg
- Department of Clinical Sciences in Malmö, Ophthalmology, Lund University, Malmö, Sweden
- Department of Ophthalmology, Skåne University Hospital, Malmö, Sweden
| | - Anders Heijl
- Department of Clinical Sciences in Malmö, Ophthalmology, Lund University, Malmö, Sweden
- Department of Ophthalmology, Skåne University Hospital, Malmö, Sweden
| | - Boel Bengtsson
- Department of Clinical Sciences in Malmö, Ophthalmology, Lund University, Malmö, Sweden
| |
Collapse
|
3
|
Daniaux M, Gruber L, Santner W, Czech T, Knapp R. Interval breast cancer: Analysis of occurrence, subtypes and implications for breast cancer screening in a model region. Eur J Radiol 2021; 143:109905. [PMID: 34403883 DOI: 10.1016/j.ejrad.2021.109905] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Revised: 08/01/2021] [Accepted: 08/06/2021] [Indexed: 01/16/2023]
Abstract
PURPOSE Interval breast carcinomas (IBC) constitute a subgroup of malignancies in women participating in a breast cancer screening programme, yet diagnosed outside of a screening appointment. Tyrol is an Austrian screening model region with a dedicated IBC board. We analysed IBC subtype distribution, demographic and biological parameters and implications for screening programmes. METHOD 161 patients with an IBC diagnosed from 2014 to 2017 were retrospectively analysed and grouped into true, occult, minimal-signs, and false negative (due to reading or technical error) IBCs cases by three independent readers. The influence of demographic and disease-related covariates were assessed. RESULTS The median interval from screening to diagnostic diagnosis was 12.8 months (range 1.1 to 23.9 months). Most cases were true (36.02%), occult (31.06%) and false-negative IBCs due to reading errors (29.81%). Interobserver agreement was rated as 'high' between all readers. Higher breast density was associated with true and occult IBCs. The rate of invasive subtypes was highest in true IBCs. Regardless of smaller tumour size in true and occult IBCs, doubling time was lower and ki-67 index higher in true and occult compared to false-negative IBCs. CONCLUSIONS True and occult IBCs present with a more aggressive biological phenotype and are associated with younger age and higher breast density. Additional yearly ultrasound examinations in women at risk may aid in the earlier detection.
Collapse
Affiliation(s)
- Martin Daniaux
- Department of Radiology, Medical University Innsbruck, Anichstraße 35, Innsbruck, Austria
| | - Leonhard Gruber
- Department of Radiology, Medical University Innsbruck, Anichstraße 35, Innsbruck, Austria.
| | - Wolfram Santner
- Department of Radiology, Privatklinik Hirslanden, Rigistrasse 1, Cham, Switzerland
| | - Theresa Czech
- Department of Gynaecology, Medical University Innsbruck, Anichstraße 35, Innsbruck, Austria
| | - Rudolf Knapp
- Department of Radiology, Bezirkskrankenhaus Kufstein, Endach 27, Kufstein, Austria
| |
Collapse
|
4
|
Kopans DB. The wisdom trial is based on faulty reasoning and has major design and execution problems. Breast Cancer Res Treat 2020; 185:549-556. [PMID: 33237397 DOI: 10.1007/s10549-020-06020-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 11/13/2020] [Indexed: 10/22/2022]
Abstract
PURPOSE To evaluate the design and plan of execution of the "WISDOM" trial. METHODS The rationale and reasoning behind the WISDOM Trial were reviewed and analyzed. The published parameters of the trial were reviewed. RESULTS The study is based on a failed understanding of the available data about breast cancer screening and is based on faulty assumptions, false reasoning, a scientifically unsupportable study design, ignoring advances in screening, a questionable endpoint, the likely lacking of power to answer the primary question, and support by insurance companies whose primary goal is almost certainly to reduce their costs. CONCLUSION A major part of the premise is that there is a "debate" about the efficacy of screening. WISDOM ignores the fact that the "debate" has been manufactured and is not science-based. The results of the WISDOM Trial may be misleading.
Collapse
Affiliation(s)
- Daniel B Kopans
- Radiology, Harvard Medical School, 20 Manitoba Road, Waban, MA, 02468, USA.
| |
Collapse
|
5
|
Salim M, Wåhlin E, Dembrower K, Azavedo E, Foukakis T, Liu Y, Smith K, Eklund M, Strand F. External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. JAMA Oncol 2020; 6:1581-1588. [PMID: 32852536 PMCID: PMC7453345 DOI: 10.1001/jamaoncol.2020.3321] [Citation(s) in RCA: 128] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2020] [Accepted: 06/02/2020] [Indexed: 12/21/2022]
Abstract
Importance A computer algorithm that performs at or above the level of radiologists in mammography screening assessment could improve the effectiveness of breast cancer screening. Objective To perform an external evaluation of 3 commercially available artificial intelligence (AI) computer-aided detection algorithms as independent mammography readers and to assess the screening performance when combined with radiologists. Design, Setting, and Participants This retrospective case-control study was based on a double-reader population-based mammography screening cohort of women screened at an academic hospital in Stockholm, Sweden, from 2008 to 2015. The study included 8805 women aged 40 to 74 years who underwent mammography screening and who did not have implants or prior breast cancer. The study sample included 739 women who were diagnosed as having breast cancer (positive) and a random sample of 8066 healthy controls (negative for breast cancer). Main Outcomes and Measures Positive follow-up findings were determined by pathology-verified diagnosis at screening or within 12 months thereafter. Negative follow-up findings were determined by a 2-year cancer-free follow-up. Three AI computer-aided detection algorithms (AI-1, AI-2, and AI-3), sourced from different vendors, yielded a continuous score for the suspicion of cancer in each mammography examination. For a decision of normal or abnormal, the cut point was defined by the mean specificity of the first-reader radiologists (96.6%). Results The median age of study participants was 60 years (interquartile range, 50-66 years) for 739 women who received a diagnosis of breast cancer and 54 years (interquartile range, 47-63 years) for 8066 healthy controls. The cases positive for cancer comprised 618 (84%) screen detected and 121 (16%) clinically detected within 12 months of the screening examination. The area under the receiver operating curve for cancer detection was 0.956 (95% CI, 0.948-0.965) for AI-1, 0.922 (95% CI, 0.910-0.934) for AI-2, and 0.920 (95% CI, 0.909-0.931) for AI-3. At the specificity of the radiologists, the sensitivities were 81.9% for AI-1, 67.0% for AI-2, 67.4% for AI-3, 77.4% for first-reader radiologist, and 80.1% for second-reader radiologist. Combining AI-1 with first-reader radiologists achieved 88.6% sensitivity at 93.0% specificity (abnormal defined by either of the 2 making an abnormal assessment). No other examined combination of AI algorithms and radiologists surpassed this sensitivity level. Conclusions and Relevance To our knowledge, this study is the first independent evaluation of several AI computer-aided detection algorithms for screening mammography. The results of this study indicated that a commercially available AI computer-aided detection algorithm can assess screening mammograms with a sufficient diagnostic performance to be further evaluated as an independent reader in prospective clinical trials. Combining the first readers with the best algorithm identified more cases positive for cancer than combining the first readers with second readers.
Collapse
Affiliation(s)
- Mattie Salim
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Department of Radiology, Karolinska University Hospital, Stockholm, Sweden
| | - Erik Wåhlin
- Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Karin Dembrower
- Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden
- Department of Radiology, Capio Sankt Görans Hospital, Stockholm, Sweden
| | - Edward Azavedo
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
| | - Theodoros Foukakis
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Department of Radiology, Karolinska University Hospital, Stockholm, Sweden
| | - Yue Liu
- Division of Computational Science and Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden
| | - Kevin Smith
- KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden
| | - Martin Eklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Fredrik Strand
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Breast Radiology, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
6
|
Hsu CY, Hsu WF, Yen AMF, Chen HH. Sampling-based Markov regression model for multistate disease progression: Applications to population-based cancer screening program. Stat Methods Med Res 2019; 29:2198-2216. [PMID: 31744392 DOI: 10.1177/0962280219885400] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To develop personalized screening and surveillance strategies, the information required to superimpose state-specific covariates into the multi-step progression of disease natural history often relies on the entire population-based screening data, which are costly and infeasible particularly when a new biomarker is proposed. Following Prentice's case-cohort concept, a non-standard case-cohort design from a previous study has been adapted for constructing multistate disease natural history with two-stage sampling. Nonetheless, the use of data only from first screens may invoke length-bias and fail to consider the test sensitivity. Therefore, a new sampling-based Markov regression model and its variants are proposed to accommodate additional subsequent follow-up data on various detection modes to construct state-specific covariate-based multistate disease natural history with accuracy and efficiency. Computer simulation algorithms for determining the required sample size and the sampling fraction of each detection mode were developed either through power function or the capacity of screening program. The former is illustrated with breast cancer screening data from which the effect size and the required sample size regarding the effect of BRCA on multistate outcome of breast cancer were estimated. The latter is applied to population-based colorectal cancer screening data to identify the optimal sampling fraction of each detection mode.
Collapse
Affiliation(s)
- Chen-Yang Hsu
- Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei.,School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei
| | - Wen-Feng Hsu
- Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei.,Department of Internal Medicine, National Taiwan University Hospital, Taipei
| | - Amy Ming-Fang Yen
- Department of Internal Medicine, National Taiwan University Hospital, Taipei
| | - Hsiu-Hsi Chen
- Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei.,Innovation and Policy Center for Population Health and Sustainable Environment, College of Public Health, National Taiwan University, Taipei
| |
Collapse
|
7
|
Feig SA. Evidence of Benefit from Mammography Screening of Average-Risk Women Ages 40-49 Years: Science, Metrics, and Value Judgments. JOURNAL OF BREAST IMAGING 2019; 1:78-83. [PMID: 38424920 DOI: 10.1093/jbi/wbz010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Indexed: 03/02/2024]
Abstract
The majority of randomized control trials and service-based screening studies of women ages 40-49 years demonstrate reductions in mortality of 29%-48% when long-term outcome is assessed. Annual screening is preferable in these younger women due to faster tumor-doubling times. Advances in mammography technique and breast ultrasound may allow even better results in the future.
Collapse
Affiliation(s)
- Stephen A Feig
- University of California Irvine, Department of Radiological Sciences, Orange, CA
| |
Collapse
|
8
|
Wald N, Chamberlain J, Hackshaw A. Report of the European Society of Mastology Breast Cancer Screening Evaluation Committee. TUMORI JOURNAL 2018; 79:371-9. [PMID: 8171734 DOI: 10.1177/030089169307900601] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- N Wald
- Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, St. Batholomew's Hospital Medical College, Charterhouse Square, London, U.K
| | | | | |
Collapse
|
9
|
Combined screening with mammography and ultrasound in a population-based screening program. Eur J Radiol 2018; 101:24-29. [DOI: 10.1016/j.ejrad.2018.01.022] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 01/20/2018] [Accepted: 01/22/2018] [Indexed: 11/20/2022]
|
10
|
Kopans DB. Breast cancer screening: Where have we been and where are we going? A personal perspective based on history, data and experience. Clin Imaging 2018; 48:vii-xi. [DOI: 10.1016/j.clinimag.2017.12.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 12/21/2017] [Indexed: 11/27/2022]
|
11
|
Kopans DB. Breast cancer screening: Where have we been and where are we going? A personal perspective based on history, data and experience. Clin Imaging 2017; 50:91-95. [PMID: 29331672 DOI: 10.1016/j.clinimag.2017.12.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 12/21/2017] [Indexed: 01/22/2023]
Abstract
It is important to understand the history of breast cancer screening to better understand the continuing effort to reduce access to screening. Since the randomized, controlled trials have shown a statistically significant mortality reduction for women ages 40-74, the appropriate threshold for initiating screening is age 40 with no data to support the use of the age of 50 as a threshold for screening. All women are at risk for developing breast cancer and all women should have access to screening.
Collapse
Affiliation(s)
- Daniel B Kopans
- Radiology Harvard Medical School, Founder Bresat Imagning Division Massachusetts General Hospital, 20 Manitoba Road, Waban, MA 02468, United States.
| |
Collapse
|
12
|
Abstract
Breast cancer is the most commonly diagnosed cancer in women in the United States and the second leading cause of cancer death in American women (1). Regular screening mammography starting at age 40 years reduces breast cancer mortality in average-risk women (2). Screening, however, also exposes women to harm through false-positive test results and overdiagnosis of biologically indolent lesions. Differences in balancing benefits and harms have led to differences among major guidelines about what age to start, what age to stop, and how frequently to recommend mammography screening in average-risk women (2-4).Breast cancer risk assessment is very important for identifying women who may benefit from more intensive breast cancer surveillance; however, there is no standardized approach to office-based breast cancer risk assessment in the United States. This can lead to missed opportunities to identify women at high risk of breast cancer and may result in applying average-risk screening recommendations to high-risk women. Risk assessment and identification of women at high risk allow for referral to health care providers with expertise in cancer genetics counseling and testing for breast cancer-related germline mutations (eg, BRCA), patient counseling about risk-reduction options, and cascade testing to identify family members who also may be at increased risk.The purpose of this Practice Bulletin is to discuss breast cancer risk assessment, review breast cancer screening guidelines in average-risk women, and outline some of the controversies surrounding breast cancer screening. It will present recommendations for using a framework of shared decision making to assist women in balancing their personal values regarding benefits and harms of screening at various ages and intervals to make personal screening choices from within a range of reasonable options. Recommendations for women at elevated risk and discussion of new technologies, such as tomosynthesis, are beyond the scope of this document and are addressed in other publications of the American College of Obstetricians and Gynecologists (ACOG) (5-7).
Collapse
|
13
|
Ray KM, Price ER, Joe BN. Evidence to Support Screening Women in Their 40s. Radiol Clin North Am 2017; 55:429-439. [DOI: 10.1016/j.rcl.2016.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Hsu CY, Yen MF, Auvinen A, Chiu YH, Chen HH. Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. Stat Methods Med Res 2016; 27:2519-2539. [DOI: 10.1177/0962280216682284] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Population-based cancer screening is often asked but hardly addressed by a question: “How many rounds of screening are required before identifying a cancer of interest staying in the pre-clinical detectable phase (PCDP)?” and also a similar one related to the number of screens required for stopping screening for the low risk group. It can be answered by using longitudinal follow-up data on repeated rounds of screen, namely periodic screen, but such kind of data are rather complicated and fraught with intractable statistical properties including correlated multistate outcomes, unobserved and incomplete (censoring or truncation) information, and imperfect measurements. We therefore developed a negative-binomial-family-based discrete-time stochastic process, taking sensitivity and specificity into account, to accommodate these thorny issues. The estimation of parameters was implemented with Bayesian Markov Chain Monte Carlo method. We demonstrated how to apply this proposed negative-binomial-family-based model to the empirical data similar to the Finnish breast cancer screening program.
Collapse
Affiliation(s)
- Chen-Yang Hsu
- Division of Biostatistics, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Ming-Fang Yen
- School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
| | - Anssi Auvinen
- Tampere School of Health Science, University of Tampere, Tampere, Finland
| | - Yueh-Hsia Chiu
- Department of Health Care Management, College of Management, Chang Gung University, Tao-Yuan, Taiwan
| | - Hsiu-Hsi Chen
- Division of Biostatistics, College of Public Health, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
15
|
Hofvind S, Bjurstam N, Sørum R, Bjørndal H, Thoresen S, Skaane P. Number and characteristics of breast cancer cases diagnosed in four periods in the screening interval of a biennial population-based screening programme. J Med Screen 2016; 13:192-6. [PMID: 17217608 DOI: 10.1177/096914130601300406] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objective To describe the distribution and prognostic tumour characteristics of interval breast cancers diagnosed in four periods after index screen (1-6, 7-12, 13-18 and 19+ months) in a population-based screening programme inviting women aged 50–69 years to biennial screening. Setting The Norwegian Breast Cancer Screening Programme (NBCSP) Methods In all, 848 interval breast cancer cases were diagnosed in 437,235 screening examinations. The distribution and prognostic tumour characteristics of the interval cancers diagnosed in four periods in the screening interval will be described. Proportions and rates will be compared by χ2-test. Results A total of 70% of the interval cancers in the NBCSP were diagnosed in the second year of the interval. Except for tumour size (P = 0.027), we found no evidence of adverse prognostic breast characteristics (grade, lymph node involvement, oestrogen and progesterone receptor positive) in invasive tumours diagnosed during the second versus the first year of the screening interval (Chi square P 0.05 for all). The prognostic characteristics of the tumours did not differ by age groups. It was a decreasing interval cancer rate per 10,000 women-years by age. Conclusion The risk of interval cancer increases by time after index screen, and 70% of the interval cancers in the NBCSP were diagnosed in the second year of the interval. Prognostic histological tumour characteristics did not differ by time after index screen, thus mean sojourn time (tumour growth rate) seems important for stating an optimal screening interval in a population-based screening programme.
Collapse
|
16
|
Li J, Ivansson E, Klevebring D, Tobin NP, Lindström LS, Holm J, Prochazka G, Cristando C, Palmgren J, Törnberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Grönberg H, Czene K. Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clin Cancer Res 2016; 23:2584-2592. [DOI: 10.1158/1078-0432.ccr-16-0967] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 08/08/2016] [Accepted: 08/15/2016] [Indexed: 11/16/2022]
|
17
|
Tabar L, Chen THH, Hsu CY, Wu WYY, Yen AMF, Chen SLS, Chiu SYH, Fann JCY, Beckmann K, Smith RA, Duffy SW. Evaluation issues in the Swedish Two-County Trial of breast cancer screening: An historical review. J Med Screen 2016; 24:27-33. [PMID: 27098311 PMCID: PMC5308404 DOI: 10.1177/0969141316631375] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Objectives To summarize debate and research in the Swedish Two-County Trial of mammographic screening on key issues of trial design, endpoint evaluation, and overdiagnosis, and from these to infer promising directions for the future. Methods A cluster-randomized controlled trial of the offer of breast cancer screening in Sweden, with a single screen of the control group at the end of the screening phase forms the setting for a historical review of investigations and debate on issues of design, analysis, and interpretation of results of the trial. Results There has been considerable commentary on the closure screen of the control group, ascertainment of cause of death, and cluster randomization. The issues raised were researched in detail and the main questions answered in publications between 1989 and 2003. Overdiagnosis issues still remain, but methods of estimation taking full account of lead time and of non-screening influences on incidence (taking place mainly before 2005) suggest that it is a minor phenomenon. Conclusion Despite resolution of issues relating to this trial in peer-reviewed publications dating from years, or even decades ago, issues that already have been addressed continue to be raised. We suggest that it would be more profitable to concentrate efforts on current research issues in breast cancer diagnosis, treatment, and prevention.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Stephen W Duffy
- Queen Mary University of London, London, UK
- SW Duffy, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
| |
Collapse
|
18
|
Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DSM, Henderson LM, Smith RA. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status. JAMA Oncol 2016; 1:1069-77. [PMID: 26501844 DOI: 10.1001/jamaoncol.2015.3084] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
IMPORTANCE Screening mammography intervals remain under debate in the United States. OBJECTIVE To compare the proportion of breast cancers with less vs more favorable prognostic characteristics in women screening annually vs biennially by age, menopausal status, and postmenopausal hormone therapy (HT) use. DESIGN, SETTING, AND PARTICIPANTS This was a study of a prospective cohort from 1996 to 2012 at Breast Cancer Surveillance Consortium facilities. A total of 15,440 women ages 40 to 85 years with breast cancer diagnosed within 1 year of an annual or within 2 years of a biennial screening mammogram. EXPOSURES We updated previous analyses by using narrower intervals for defining annual (11-14 months) and biennial (23-26 months) screening. MAIN OUTCOMES AND MEASURES We defined less favorable prognostic characteristics as tumors that were stage IIB or higher, size greater than 15 mm, positive nodes, and any 1 or more of these characteristics. We used log-binomial regression to model the proportion of breast cancers with less favorable characteristics following a biennial vs annual screen by 10-year age groups and by menopausal status and current postmenopausal HT use. RESULTS Among 15,440 women with breast cancer, most were 50 years or older (13,182 [85.4%]), white (12,063 [78.1%]), and postmenopausal (9823 [63.6%]). Among 2027 premenopausal women (13.1%), biennial screeners had higher proportions of tumors that were stage IIB or higher (relative risk [RR], 1.28 [95% CI, 1.01-1.63]; P=.04), size greater than 15 mm (RR, 1.21 [95% CI, 1.07-1.37]; P=.002), and with any less favorable prognostic characteristic (RR, 1.11 [95% CI, 1.00-1.22]; P=.047) compared with annual screeners. Among women currently taking postmenopausal HT, biennial screeners tended to have tumors with less favorable prognostic characteristics compared with annual screeners; however, 95% CIs were wide, and differences were not statistically significant (for stage 2B+, RR, 1.14 [95% CI, 0.89-1.47], P=.29; size>15 mm, RR, 1.13 [95% CI, 0.98-1.31], P=.09; node positive, RR, 1.18 [95% CI, 0.98-1.42], P=.09; any less favorable characteristic, RR, 1.12 [95% CI, 1.00-1.25], P=.053). The proportions of tumors with less favorable prognostic characteristics were not significantly larger for biennial vs annual screeners among postmenopausal women not taking HT (eg, any characteristic: RR, 1.03 [95% CI, 0.95-1.12]; P=.45), postmenopausal HT users after subdividing by type of hormone use (eg, any characteristic: estrogen+progestogen users, RR, 1.16 [95% CI, 0.91-1.47]; P=.22; estrogen-only users, RR, 1.14 [95% CI, 0.94-1.37]; P=.18), or any 10-year age group (eg, any characteristic: ages 40-49 years, RR, .1.04 [95% CI, 0.94-1.14]; P=.48; ages 50-59 years, RR, 1.03 [95% CI, 0.94-1.12]; P=.58; ages 60-69 years, RR, 1.07 [95% CI, 0.97-1.19]; P=.18; ages 70-85 years, RR, 1.05 [95% CI, 0.94-1.18]; P=.35). CONCLUSIONS AND RELEVANCE Premenopausal women diagnosed as having breast cancer following biennial vs annual screening mammography are more likely to have tumors with less favorable prognostic characteristics. Postmenopausal women not using HT who are diagnosed as having breast cancer following a biennial or annual screen have similar proportions of tumors with less favorable prognostic characteristics.
Collapse
Affiliation(s)
- Diana L Miglioretti
- Division of Biostatistics, Department of Public Health Sciences, University of California Davis School of Medicine, Davis2Group Health Research Institute, Group Health Cooperative, Seattle, Washington
| | - Weiwei Zhu
- Group Health Research Institute, Group Health Cooperative, Seattle, Washington
| | - Karla Kerlikowske
- Departments of Medicine and Epidemiology and Biostatistics, University of California-San Francisco, San Francisco,4General Internal Medicine Section, Department of Veterans Affairs, University of California-San Francisco, San Francisco
| | - Brian L Sprague
- Department of Surgery, Office of Health Promotion Research, University of Vermont College of Medicine, Burlington6University of Vermont Cancer Center, University of Vermont College of Medicine, Burlington
| | - Tracy Onega
- Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire8Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
| | - Diana S M Buist
- Group Health Research Institute, Group Health Cooperative, Seattle, Washington
| | | | - Robert A Smith
- Cancer Control Science Department, American Cancer Society, Atlanta, Georgia
| | | |
Collapse
|
19
|
Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, Kerlikowske K, Fenton JJ, Melnikow J, de Koning HJ, Hubbard RA. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med 2016; 164:205-14. [PMID: 26756460 PMCID: PMC4878445 DOI: 10.7326/m15-1241] [Citation(s) in RCA: 93] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Estimates of risk for radiation-induced breast cancer from mammography screening have not considered variation in dose exposure or diagnostic work-up after abnormal screening results. OBJECTIVE To estimate distributions of radiation-induced breast cancer incidence and mortality from digital mammography screening while considering exposure from screening and diagnostic mammography and dose variation among women. DESIGN 2 simulation-modeling approaches. SETTING U.S. population. PATIENTS Women aged 40 to 74 years. INTERVENTION Annual or biennial digital mammography screening from age 40, 45, or 50 years until age 74 years. MEASUREMENTS Lifetime breast cancer deaths averted (benefits) and radiation-induced breast cancer incidence and mortality (harms) per 100,000 women screened. RESULTS Annual screening of 100,000 women aged 40 to 74 years was projected to induce 125 breast cancer cases (95% CI, 88 to 178) leading to 16 deaths (CI, 11 to 23), relative to 968 breast cancer deaths averted by early detection from screening. Women exposed at the 95th percentile were projected to develop 246 cases of radiation-induced breast cancer leading to 32 deaths per 100,000 women. Women with large breasts requiring extra views for complete examination (8% of population) were projected to have greater radiation-induced breast cancer risk (266 cancer cases and 35 deaths per 100,000 women) than other women (113 cancer cases and 15 deaths per 100,000 women). Biennial screening starting at age 50 years reduced risk for radiation-induced cancer 5-fold. LIMITATION Life-years lost from radiation-induced breast cancer could not be estimated. CONCLUSION Radiation-induced breast cancer incidence and mortality from digital mammography screening are affected by dose variability from screening, resultant diagnostic work-up, initiation age, and screening frequency. Women with large breasts may have a greater risk for radiation-induced breast cancer. PRIMARY FUNDING SOURCE Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, National Cancer Institute.
Collapse
Affiliation(s)
- Diana L. Miglioretti
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Jane Lange
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Jeroen J. van den Broek
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Christoph I. Lee
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Nicolien T. van Ravesteyn
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Dominique Ritley
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Karla Kerlikowske
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Joshua J. Fenton
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Joy Melnikow
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Harry J. de Koning
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| | - Rebecca A. Hubbard
- From University of California, Davis, School of Medicine, Davis, California; University of California, Davis, Sacramento, California; Group Health Research Institute, University of Washington, and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; University of California, San Francisco, San Francisco, California
- and University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
20
|
Personalized Screening for Breast Cancer: A Wolf in Sheep's Clothing? AJR Am J Roentgenol 2015; 205:1365-71. [DOI: 10.2214/ajr.15.15293] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
21
|
Breast Cancer Characteristics Associated With Digital Versus Film-Screen Mammography for Screen-Detected and Interval Cancers. AJR Am J Roentgenol 2015; 205:676-84. [PMID: 26295657 DOI: 10.2214/ajr.14.13904] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The purpose of this study was to determine whether pathologic findings of screen-detected and interval cancers differ for digital versus film mammography. MATERIALS AND METHODS Breast Cancer Surveillance Consortium data from 2003-2011 on 3,021,515 screening mammograms (40.3% digital, 59.7% film) of women 40-89 years old were reviewed. Cancers were considered screen detected if diagnosed within 12 months of an examination with positive findings and interval if diagnosed within 12 months of an examination with negative findings. Tumor characteristics for screen-detected and interval cancers were compared for digital versus film mammography by use of logistic regression models to estimate the odds ratio and 95% CI with adjustment for age, race and ethnicity, hormone therapy use, screening interval, examination year, and registry. Generalized estimating equations were used to account for correlation within facilities. RESULTS Among 15,729 breast cancers, 85.3% were screen detected and 14.7% were interval. Digital and film mammography had similar rates of screen-detected (4.47 vs 4.42 per 1000 examinations) and interval (0.73 vs 0.79 per 1000 examinations) cancers for digital versus film. In adjusted analyses, interval cancers diagnosed after digital examinations with negative findings were less likely to be American Joint Committee on Cancer stage IIB or higher (odds ratio, 0.69; 95% CI, 0.52-0.93), have positive nodal status (odds ratio, 0.78; 95% CI, 0.64-0.95), or be estrogen receptor negative (odds ratio, 0.71; 95% CI, 0.56-0.91) than were interval cancers diagnosed after a film examination with negative findings. CONCLUSION Screen-detected cancers diagnosed after digital and film mammography had similar rates of unfavorable tumor characteristics. Interval-detected cancers diagnosed after a digital examination were less likely to have unfavorable tumor features than those diagnosed after film mammography, but the absolute differences were small.
Collapse
|
22
|
Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih YCT, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AMD, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA 2015; 314:1599-614. [PMID: 26501536 PMCID: PMC4831582 DOI: 10.1001/jama.2015.12783] [Citation(s) in RCA: 1040] [Impact Index Per Article: 115.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
IMPORTANCE Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality. OBJECTIVE To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer. PROCESS The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. EVIDENCE SYNTHESIS Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk. RECOMMENDATIONS The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation). CONCLUSIONS AND RELEVANCE These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening.
Collapse
Affiliation(s)
| | | | - Ruth Etzioni
- University of Washington and the Fred Hutchinson Cancer Research Center, Seattle
| | | | | | | | - Louise C Walter
- University of California, San Francisco, and San Francisco VA Medical Center
| | - Timothy R Church
- Masonic Cancer Center and the University of Minnesota, Minneapolis
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
“Do Unto Others as You Would Have Them Do Unto You”: Breast Imagers' Perspectives Regarding Screening Mammography for Others and for Themselves—Do They Practice What They Preach? AJR Am J Roentgenol 2015; 204:1336-44. [DOI: 10.2214/ajr.14.13237] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
24
|
Abstract
Numerous clinical studies have confirmed that screening women age 40 years and older reduces breast cancer mortality by 30% to 50%. Several factors including faster breast cancer growth rates and lower breast cancer incidence among younger women, as well as shorter life expectancy and more comorbid conditions among older women, should also be considered in screening guidelines. Annual screening beginning at age 40 years and continuing with no upper age limit, as long as a woman has a life expectancy of at least 5 years and no significant comorbid conditions, is currently recommended.
Collapse
Affiliation(s)
- Stephen A Feig
- Department of Radiological Sciences, University of California Irvine Medical Center, 101 City Drive South, Orange, CA 92869-3298, USA.
| |
Collapse
|
25
|
Erpeldinger S, Fayolle L, Boussageon R, Flori M, Lainé X, Moreau A, Gueyffier F. Is there excess mortality in women screened with mammography: a meta-analysis of non-breast cancer mortality. Trials 2013; 14:368. [PMID: 24192052 PMCID: PMC4228242 DOI: 10.1186/1745-6215-14-368] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Accepted: 10/21/2013] [Indexed: 12/22/2022] Open
Abstract
Background The objective of our meta-analysis and systematic review was to analyze non-breast cancer mortality in women screened with mammography versus non-screened women to determine whether there is excess mortality caused by screening. Methods We searched PubMed and the Web of Science up to 30 November 2010. We included randomized controlled trials with non-breast cancer mortality as the main endpoint. Two authors independently assessed trial quality and extracted data. Results There was no significant difference between groups at 13-year follow-up (odds ratio = 1.00 (95% CI 0.98 to 1.03) with average heterogeneity I2 = 61%) regardless of the age and the methodological quality of the included studies. The meta-analysis did not reveal excess non-breast cancer mortality caused by screening. If screening does have an effect on excess mortality, it is possible to provide an estimate of its maximum value through the upper confidence interval in good-quality methodological studies: up to 3% in the screened women group (12 deaths per 100,000 women). Conclusions The all-cause death rate was not significantly reduced by screening when compared to the rate observed in unscreened women. However, mammography screening does not seem to induce excess mortality. These findings improve information given to patients. Finding more comprehensive data is now going to be difficult given the complexity of the studies. Individual modeling should be used because the studies fail to include all the aspects of a complex situation. The risk/benefit analysis of screening needs to be regularly and independently reassessed.
Collapse
Affiliation(s)
- Sylvie Erpeldinger
- Department of General Medicine, Université Claude Bernard Lyon1, 69000, Lyon, France.
| | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
BACKGROUND A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary. OBJECTIVES To assess the effect of screening for breast cancer with mammography on mortality and morbidity. SEARCH METHODS We searched PubMed (22 November 2012) and the World Health Organization's International Clinical Trials Registry Platform (22 November 2012). SELECTION CRITERIA Randomised trials comparing mammographic screening with no mammographic screening. DATA COLLECTION AND ANALYSIS Two authors independently extracted data. Study authors were contacted for additional information. MAIN RESULTS Eight eligible trials were identified. We excluded a trial because the randomisation had failed to produce comparable groups.The eligible trials included 600,000 women in the analyses in the age range 39 to 74 years. Three trials with adequate randomisation did not show a statistically significant reduction in breast cancer mortality at 13 years (relative risk (RR) 0.90, 95% confidence interval (CI) 0.79 to 1.02); four trials with suboptimal randomisation showed a significant reduction in breast cancer mortality with an RR of 0.75 (95% CI 0.67 to 0.83). The RR for all seven trials combined was 0.81 (95% CI 0.74 to 0.87). We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death. The trials with adequate randomisation did not find an effect of screening on total cancer mortality, including breast cancer, after 10 years (RR 1.02, 95% CI 0.95 to 1.10) or on all-cause mortality after 13 years (RR 0.99, 95% CI 0.95 to 1.03).Total numbers of lumpectomies and mastectomies were significantly larger in the screened groups (RR 1.31, 95% CI 1.22 to 1.42), as were number of mastectomies (RR 1.20, 95% CI 1.08 to 1.32). The use of radiotherapy was similarly increased whereas there was no difference in the use of chemotherapy (data available in only two trials). AUTHORS' CONCLUSIONS If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and overtreatment is at 30%, it means that for every 2000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings. To help ensure that the women are fully informed before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk. Because of substantial advances in treatment and greater breast cancer awareness since the trials were carried out, it is likely that the absolute effect of screening today is smaller than in the trials. Recent observational studies show more overdiagnosis than in the trials and very little or no reduction in the incidence of advanced cancers with screening.
Collapse
Affiliation(s)
- Peter C Gøtzsche
- The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
| | | |
Collapse
|
27
|
Effects of annual vs triennial mammography interval on breast cancer incidence and mortality in ages 40-49 in Finland. Br J Cancer 2011; 105:1388-91. [PMID: 21934688 PMCID: PMC3241549 DOI: 10.1038/bjc.2011.372] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: The aim of this study was to evaluate the effects of mammography screening invitation interval on breast cancer mortality in women aged 40–49 years. Methods: Since 1987 in Turku, Finland, women aged 40–49 years and born in even calendar years were invited for mammography screening annually and those born in odd years triennially. The female cohorts born during 1945–1955 were followed for up to 10 years for incident breast cancers and thereafter for an additional 3 years for mortality. Results: Among 14 765 women free of breast cancer at age 40, there were 207 incident primary invasive breast cancers diagnosed before the age of 50. Of these, 36 women died of breast cancer. The mean follow-up time for cancer incidence was 9.8 years and for mortality 12.8 years. The incidence of breast cancer was similar in the annual and triennial invitation groups (RR: 0.98, 95% confidence interval (CI): 0.75–1.29). Further, there were no significant differences in overall mortality (RR: 1.20, 95% CI: 0.99–1.46) or in incidence-based breast cancer mortality (RR: 1.14, 95% CI: 0.59–1.27) between the annual and triennial invitation groups. Conclusions: There were no differences in the incidence of breast cancer or incidence-based breast cancer mortality between the women who were invited for screening annually or triennially.
Collapse
|
28
|
Ganai S, Winchester DJ. Screening mammography. Cancer 2011; 117:3062-3. [DOI: 10.1002/cncr.26319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
29
|
Breast screening policy: are we heading in the right direction? Clin Radiol 2011; 66:915-9. [PMID: 21741631 DOI: 10.1016/j.crad.2011.03.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2010] [Revised: 02/25/2011] [Accepted: 03/02/2011] [Indexed: 11/20/2022]
Abstract
There is a large body of evidence supporting 2-yearly screening of women aged 50-69 years. There is good evidence for a mortality reduction from mammographic screening in women aged 40 to 49 years but a 1-year interval is required. The lack of specificity of screening in young women does remain a problem. There is no evidence to suggest that a single screen between the ages of 47 and 50 years within a programme screening at 3-year intervals will reduce mortality; the trials showing a mortality benefit in women in their 40s included multiple screening episodes and shorter screening intervals. There is no randomized, controlled trial evidence to support screening in women aged above 70 years and screening this age group will cause greater harm than in younger women through higher rates of over-diagnosis and consequent over-treatment. The randomized phase of the screening age extension, which at the moment is planned to last only 6 years, should not be immediately followed by general implementation of the policy. Only if and when additional mortality reductions and an acceptable balance between benefit and harms are shown to be achieved by the extra screens should the 2007 Cancer Reform Strategy policy on age extension be implemented. Resources saved by delaying or abandoning the roll-out of the age extension could potentially be redirected towards reducing the current 3 year screening interval to 2 years in women aged 50-69 years. However, reducing the screening interval to 2 years for women aged 50-69 years would require significantly more screening invitations and resources than the proposed age extension.
Collapse
|
30
|
Zorzi M, Guzzinati S, Puliti D, Paci E. A simple method to estimate the episode and programme sensitivity of breast cancer screening programmes. J Med Screen 2011; 17:132-8. [PMID: 20956723 DOI: 10.1258/jms.2010.009060] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND The estimation of breast cancer screening sensitivity is a major aim in the quality assessment of screening programmes. The proportional incidence method for the estimation of the sensitivity of breast cancer screening programmes is rarely used to estimate the underlying incidence rates. METHODS We present a method to estimate episode and programme sensitivity of screening programmes, based solely on cancers detected within screening cycles (excluding breast cancer cases at prevalent screening round) and on the number of incident cases in the total target population (steady state). The assumptions, strengths and limitations of the method are discussed. An example of calculation of episode and programme sensitivities is given, on the basis of the data from the IMPACT study, a large observational study of breast cancer screening programmes in Italy. RESULTS The programme sensitivity from the fifth year of screening onwards ranged between 41% and 48% of the total number of cases in the target population. At steady state episode sensitivity was 0.70, with a trend across age groups, with lowest values in women aged 50-54 years (0.52) and highest in those 65-69 (0.77). CONCLUSIONS The method is a very serviceable tool for estimating sensitivity in service screening programmes, and the results are comparable with those of other methods of estimation.
Collapse
Affiliation(s)
- Manuel Zorzi
- Venetian Tumour Registry, Istituto Oncologico Veneto - IOV IRCCS, Passaggio Gaudenzio, 1, 35131 Padua, Italy.
| | | | | | | | | |
Collapse
|
31
|
Abstract
BACKGROUND A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary. OBJECTIVES To assess the effect of screening for breast cancer with mammography on mortality and morbidity. SEARCH STRATEGY We searched PubMed (November 2008). SELECTION CRITERIA Randomised trials comparing mammographic screening with no mammographic screening. DATA COLLECTION AND ANALYSIS Both authors independently extracted data. Study authors were contacted for additional information. MAIN RESULTS Eight eligible trials were identified. We excluded a biased trial and included 600,000 women in the analyses. Three trials with adequate randomisation did not show a significant reduction in breast cancer mortality at 13 years (relative risk (RR) 0.90, 95% confidence interval (CI) 0.79 to 1.02); four trials with suboptimal randomisation showed a significant reduction in breast cancer mortality with an RR of 0.75 (95% CI 0.67 to 0.83). The RR for all seven trials combined was 0.81 (95% CI 0.74 to 0.87). We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death. The trials with adequate randomisation did not find an effect of screening on cancer mortality, including breast cancer, after 10 years (RR 1.02, 95% CI 0.95 to 1.10) or on all-cause mortality after 13 years (RR 0.99, 95% CI 0.95 to 1.03).Numbers of lumpectomies and mastectomies were significantly larger in the screened groups (RR 1.31, 95% CI 1.22 to 1.42) for the two adequately randomised trials that measured this outcome; the use of radiotherapy was similarly increased. AUTHORS' CONCLUSIONS Screening is likely to reduce breast cancer mortality. As the effect was lowest in the adequately randomised trials, a reasonable estimate is a 15% reduction corresponding to an absolute risk reduction of 0.05%. Screening led to 30% overdiagnosis and overtreatment, or an absolute risk increase of 0.5%. This means that for every 2000 women invited for screening throughout 10 years, one will have her life prolonged and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress for many months because of false positive findings. It is thus not clear whether screening does more good than harm. To help ensure that the women are fully informed of both benefits and harms before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk.
Collapse
Affiliation(s)
- Peter C Gøtzsche
- The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, 3343, Copenhagen, Denmark, DK-2100
| | | |
Collapse
|
32
|
Chang JC, Chen THH, Duffy SW, Yen AMF, Chen SLS. Decision modelling of economic evaluation of intervention programme of breast cancer. J Eval Clin Pract 2010; 16:1282-8. [PMID: 20831661 DOI: 10.1111/j.1365-2753.2009.01329.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Economic appraisal of an intervention is a complex and multivariable problem, with probabilistic issues related not only to clinical outcomes but also to costs and willingness to pay. METHODS We provide a comprehensive framework for economic appraisal of a health intervention to prevent beast cancer mortality, involving probabilistic model of costs as well as of aspects of the disease process. The economic appraisal can give a range of probabilities of cost-effectiveness depending on willingness or ability to pay. RESULTS We apply the method to the example of polychemotherapy for early breast cancer. Results indicate a 30% probability of cost-effectiveness for a willingness to pay of $ 60,000 per quality-adjusted life-year and around 50% for a threshold of $ 100,000. CONCLUSION The comprehensive economic appraisal model is a powerful tool for decision making over a range of economic environments.
Collapse
Affiliation(s)
- Jung-Chen Chang
- Department of Geriatric Health Promotion, College of Healthcare Management, Kainan University, Taoyuan County, Taiwan
| | | | | | | | | |
Collapse
|
33
|
Abstract
The most rigorous and valid approach to evaluating cancer screening modalities is the randomized controlled trial (RCT). RCTs are major undertakings and the intricacies of trial design, operations, and management are generally underappreciated by the typical researcher. The purpose of this article is to inform the reader of the "nuts and bolts" of designing and conducting cancer screening RCTs. Following a brief introduction as to why RCTs are critical in evaluating screening modalities, we discuss design considerations, including the choice of design type and duration of follow-up. We next present an approach to sample-size calculations. We then discuss aspects of trial implementation, including recruitment, randomization, and data management. A discussion of commonly employed data analyses comes next, and includes methods for the primary analysis (comparison of cause-specific mortality rates between the screened and control arms for the cancer of interest), as well as for secondary endpoints such as sensitivity. We follow with a discussion of sequential monitoring and interim analysis techniques, which are used to examine the primary outcome while the trial is ongoing. We close with thoughts on lessons learned from past cancer screening RCTs and provide recommendations for future trials. Throughout the presentation we illustrate topics with examples from completed or ongoing RCTs, including the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the National Lung Screening Trial (NLST).
Collapse
Affiliation(s)
- Philip C Prorok
- Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA.
| | | |
Collapse
|
34
|
Abstract
The objective of this study was to assess detection rates and interval breast cancer (IC) rates from eight programmes in the European Breast Cancer Screening Network. A common data collection protocol was used to explore differences in IC rates among programmes and discuss their potential determinants. Pooled analysis was used to describe IC rates by age, compliance in screening, recall rate, screening detection (SD) rate and expected breast cancer incidence. Participation in screening averaged 77.9% (range 42.6-88.7%), recall rate 5.4% (range 3.3-17.7%) in the initial and 3.4% (range 1.8-8.9%) in the subsequent screening rounds, and SD rate was 60.4 (range 41.6-91) per 10 000 women in initial and 38.5 (range 31.3-62.6) in subsequent screens. IC rate during first 12 months after screening was 5.9 (range 2.1-7.3) per 10 000 women screened negative and 12.6 (range 6.3-15) in the second year of the interval. IC comprised 28% of the IC and SD cancers. The ratio between IC rate and expected incidence was 0.29 for the first 12 months and 0.63 for the 13-24 months period. Sensitivity was higher for the ages 60-69 years and for initial tests than subsequent tests. There were distinct differences in the IC rates between programmes. The results of this study reveal large variations in screening sensitivity and performance. Pooled evaluation of some process indicators within the European breast cancer screening programmes proved to be feasible and is likely to be useful for the future, particularly if it is performed regularly and extensively.
Collapse
|
35
|
Abstract
BACKGROUND A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary. OBJECTIVES To assess the effect of screening for breast cancer with mammography on mortality and morbidity. SEARCH STRATEGY We searched PubMed (November 2008). SELECTION CRITERIA Randomised trials comparing mammographic screening with no mammographic screening. DATA COLLECTION AND ANALYSIS Both authors independently extracted data. Study authors were contacted for additional information. MAIN RESULTS Eight eligible trials were identified. We excluded a biased trial and included 600,000 women in the analyses. Three trials with adequate randomisation did not show a significant reduction in breast cancer mortality at 13 years (relative risk (RR) 0.90, 95% confidence interval (CI) 0.79 to 1.02); four trials with suboptimal randomisation showed a significant reduction in breast cancer mortality with an RR of 0.75 (95% CI 0.67 to 0.83). The RR for all seven trials combined was 0.81 (95% CI 0.74 to 0.87). We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death. The trials with adequate randomisation did not find an effect of screening on cancer mortality, including breast cancer, after 10 years (RR 1.02, 95% CI 0.95 to 1.10) or on all-cause mortality after 13 years (RR 0.99, 95% CI 0.95 to 1.03).Numbers of lumpectomies and mastectomies were significantly larger in the screened groups (RR 1.31, 95% CI 1.22 to 1.42) for the two adequately randomised trials that measured this outcome; the use of radiotherapy was similarly increased. AUTHORS' CONCLUSIONS Screening is likely to reduce breast cancer mortality. As the effect was lowest in the adequately randomised trials, a reasonable estimate is a 15% reduction corresponding to an absolute risk reduction of 0.05%. Screening led to 30% overdiagnosis and overtreatment, or an absolute risk increase of 0.5%. This means that for every 2000 women invited for screening throughout 10 years, one will have her life prolonged and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress for many months because of false positive findings. It is thus not clear whether screening does more good than harm. To help ensure that the women are fully informed of both benefits and harms before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk.
Collapse
Affiliation(s)
- Peter C Gøtzsche
- The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, 3343, Copenhagen, Denmark, 2100
| | | |
Collapse
|
36
|
Abstract
Lung cancer is the most common cause of cancer-related death in the UK. Despite aggressive primary prevention measures and improved medical care, the 5-year survival rate is less than 10% for patients in the UK who present with symptoms. The possibility of CT screening for lung cancer provides some hope of reducing mortality. However, the case for screening remains unproven. This article explores the issues surrounding lung cancer screening in the context of historical studies, trials in progress and tentative plans for a UK CT lung cancer screening trial.
Collapse
Affiliation(s)
- A J Edey
- Department of Radiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
| | | |
Collapse
|
37
|
Kakizoe T, Mucci LA, Albertsen PC, Droller MJ. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. ACTA ACUST UNITED AC 2009:191-212. [PMID: 18815934 DOI: 10.1080/03008880802284936] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Screening is used to detect disease earlier in its course, allow earlier treatment, and presumably decrease morbidities and potential mortality associated with the later expression of more advanced disease and presumably more complex treatments consequently required. Judicious screening in bladder cancer depends on an understanding of how the different forms of bladder cancer express their biological potential, whether the tools available for screening have sufficient sensitivity and specificity to have accurate predictive value in accurately diagnosing and assessing each cancer diathesis earlier in its course, and how this may influence the morbidities and mortality associated with each. The principles of screening, potential biases that can affect their accuracy and the interpretation of outcomes, tools currently available for screening, their efficacies and pitfalls, and lessons learned from studies of the role of screening in prostate cancer will be reviewed to offer an understanding of the potential role that screening may play in the different forms of bladder cancer in the context of their preclinical and treated natural history.
Collapse
Affiliation(s)
- Tadao Kakizoe
- National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
| | | | | | | |
Collapse
|
38
|
Coldman AJ, Phillips N, Olivotto IA, Gordon P, Warren L, Kan L. Impact of changing from annual to biennial mammographic screening on breast cancer outcomes in women aged 50–79 in British Columbia. J Med Screen 2008; 15:182-7. [DOI: 10.1258/jms.2008.008064] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Objectives The objective of this study was to compare breast cancer outcomes among women subject to different policies on mammography screening frequency. Setting Data were obtained for women participating in the Screening Mammography Programme of British Columbia (SMPBC) for 1988–2005. The SMPBC changed its policy for women aged 50–79 years from annual to biennial mammography in 1997, but retained an annual recommendation for women aged 40–49 years. Methods Breast cancer outcomes were compared for women participating in the programme before and after 1997 for two groups: ages 40–49 and 50–79 years. Results There were data on 658,151 women. Comparing pre-1997 and post-1997, the median interscreen interval increased by 11.1 months in women 50–79 but by only 0.3 months in women aged 40–49. Excluding those detected at initial screen, 6291 breast cancers were identified. Comparing pre-1997 and post-1997: the relative rates (RR) of screen detected cancer increased in women aged 40–49 (RR = 1.32) and the rate of invasive cancers ≥20 mm at diagnosis decreased (RR = 0.83); the rate of cancers with axillary node involvement increased in women aged 50–79 (RR = 1.23). Cancer survival improved after 1997 for women diagnosed at ages 40–49 (hazard ratio = 0.62), but was unchanged for women aged 50–79. Breast cancer mortality rates did not change between the periods in either age group. Conclusion The proximal cancer outcomes considered (staging and survival) improved in women aged 40–49 but this was offset in women aged 50–79 associated with the change in screen frequency. These changes did not result in alterations in breast cancer mortality rates in either age group.
Collapse
Affiliation(s)
- Andrew J Coldman
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Radiation Therapy Program, Vancouver Island Centre, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
| | - Norm Phillips
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Radiation Therapy Program, Vancouver Island Centre, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
| | - Ivo A Olivotto
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Radiation Therapy Program, Vancouver Island Centre, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
| | - Paula Gordon
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Radiation Therapy Program, Vancouver Island Centre, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
| | - Linda Warren
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Radiation Therapy Program, Vancouver Island Centre, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
| | - Lisa Kan
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Radiation Therapy Program, Vancouver Island Centre, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
- Screening Mammography Program of BC, British Columbia Cancer Agency, Suite 800, 686 W Broadway, Vancouver, BC V5Z 1G1, Canada
| |
Collapse
|
39
|
Coldman A, Phillips N, Warren L, Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer 2007; 120:1076-80. [PMID: 17149701 DOI: 10.1002/ijc.22249] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Mammographic screening is a proven method for the early detection of breast cancer. The authors analyzed the impact of service mammographic screening on breast cancer mortality among British Columbia women who volunteered to be screened by the Screening Mammography Program of British Columbia. A cohort of women having at least one mammographic screen by Screening Mammography Program of British Columbia between the ages of 40 and 79 in the period 1988-2003 was identified. All cases and deaths from breast cancer occurring in British Columbia were identified from the British Columbia Cancer Registry and linked to the screening cohort. Expected deaths from breast cancer in the cohort were calculated using incidence and survival rates for British Columbia women not in the cohort. Adjustment was made for age and socioeconomic status of their area of residence at time of diagnosis. The breast cancer mortality ratio was calculated by dividing observed by expected breast cancer deaths. The mortality ratio (95% confidence interval) was 0.60 (0.55, 0.65) for all ages combined (p < 0.0001). The mortality ratio in women aged 40-49 at first screening was 0.61 (0.52, 0.71), similar to that in women over 50 (p = 0.90). Exclusion of mortality associated with breast cancers diagnosed after age 50 in women starting screening in their 40s increased the mortality ratio to 0.63 (0.52, 0.77), but it remained statistically significant. Correction for self-selection bias using estimates from the literature increased the mortality ratio for all ages to 0.76. Mammographic screening at all ages between 40 and 79 reduced subsequent mortality rates from breast cancer.
Collapse
Affiliation(s)
- Andrew Coldman
- Surveillance and Outcomes Unit, British Columbia Cancer Agency, Vancouver, BC, Canada.
| | | | | | | |
Collapse
|
40
|
Postma R, Schröder FH, van Leenders GJLH, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52:89-97. [PMID: 17257742 DOI: 10.1016/j.eururo.2007.01.030] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2006] [Accepted: 01/05/2007] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To evaluate the features, rates, and characteristics of prostate cancer detected during two subsequent screening rounds. METHODS Data were retrieved from the database of European Randomized Study of Screening for Prostate Cancer (ERSPC), section Rotterdam. Men, ages 55-74 yr were screened with a 4-yr interval. Different biopsy indications were used in the first and second screens in the PSA range <4.0 ng/ml. Clinical features and a total of 1548 sextant biopsies were recorded for Gleason score and tumour extent, and 550 radical prostatectomy specimens were evaluated for Gleason score, pathologic T category, and tumour volume. RESULTS Clinical stage, Gleason score, involvement of biopsy by tumour, and PSA levels were more favourable in patients of the second round compared with those of the first round. The number of men chosen for watchful waiting increased from 98 (10%) to 123 (22%) in the second round (p<0.0001). In patients undergoing radical prostatectomy, median tumour volume in the first and second screening round was 0.65 and 0.45 ml (p=0.001). Minimal cancer (cancer <0.5 ml, organ-confined, no Gleason pattern 4 or 5) was found in 122 (31.6%) in the first and 60 (42.6%) in the second screening round (p=0.03). The 5-yr PSA progression-free survival after radical prostatectomy was 87%. CONCLUSIONS Despite the 4-yr interval an important shift of all prognostic factors occurred in favour of round 2. In those men who underwent radical prostatectomy, 42.6% fulfilled the criteria of minimal cancer. These data suggest that overdiagnosis increases with repeat screening.
Collapse
Affiliation(s)
- Renske Postma
- Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
41
|
Norman SA, Localio AR, Zhou L, Weber AL, Coates RJ, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Lee NC, Nadel MR. Benefit of screening mammography in reducing the rate of late-stage breast cancer diagnoses (United States). Cancer Causes Control 2006; 17:921-9. [PMID: 16841259 DOI: 10.1007/s10552-006-0029-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2006] [Accepted: 04/04/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE We studied the benefit of modern mammography screening in community settings, evaluating age-related differences in rates of late-stage breast cancer detection. METHODS Our multicenter population-based case-control study included 931 black and white women with incident breast cancer (American Joint Commission on Cancer Stage IIB or higher) diagnosed 1994-1998 and 4,016 randomly sampled controls never diagnosed with breast cancer. Adjusted odds ratios (ORs) estimated the relative rate of late-stage diagnosis in screened and non-screened women. RESULTS Women aged 50-64 at diagnosis with at least one screening mammogram in the previous 2 years were significantly less likely to have late-stage diagnosis (OR = 0.41, 95% CI 0.33-0.52). Results for women aged 40-49 were consistent with a screening benefit, although the confidence interval marginally overlapped the null (OR = 0.81, 95% CI 0.64-1.02). Mammography screening was associated with lower rates of late-stage breast cancer among both premenopausal (OR = 0.64, 95% CI 0.50-0.81) and postmenopausal (OR = 0.44, 95% CI 0.35-0.56) women. CONCLUSIONS With modern mammography in the community, rates of late-stage breast cancer diagnoses are lower in screened compared to non-screened women ages 40 and older, but age-related differences persist.
Collapse
Affiliation(s)
- Sandra A Norman
- Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, University of Pennsylvania, 801 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
BACKGROUND A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary. OBJECTIVES To assess the effect of screening for breast cancer with mammography on mortality and morbidity. SEARCH STRATEGY We searched PubMed (June 2005). SELECTION CRITERIA Randomised trials comparing mammographic screening with no mammographic screening. DATA COLLECTION AND ANALYSIS Both authors independently extracted data. Study authors were contacted for additional information. MAIN RESULTS Seven completed and eligible trials involving half a million women were identified. We excluded a biased trial from analysis. Two trials with adequate randomisation did not show a significant reduction in breast cancer mortality, relative risk (RR) 0.93 (95% confidence interval 0.80 to 1.09) at 13 years; four trials with suboptimal randomisation showed a significant reduction in breast cancer mortality, RR 0.75 (0.67 to 0.83) (P = 0.02 for difference between the two estimates). RR for all six trials combined was 0.80 (0.73 to 0.88). The two trials with adequate randomisation did not find an effect of screening on cancer mortality, including breast cancer, RR 1.02 (0.95 to 1.10) after 10 years, or on all-cause mortality, RR 1.00 (0.96 to 1.04) after 13 years. We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death. Numbers of lumpectomies and mastectomies were significantly larger in the screened groups, RR 1.31 (1.22 to 1.42) for the two adequately randomised trials; the use of radiotherapy was similarly increased. AUTHORS' CONCLUSIONS Screening likely reduces breast cancer mortality. Based on all trials, the reduction is 20%, but as the effect is lower in the highest quality trials, a more reasonable estimate is a 15% relative risk reduction. Based on the risk level of women in these trials, the absolute risk reduction was 0.05%. Screening also leads to overdiagnosis and overtreatment, with an estimated 30% increase, or an absolute risk increase of 0.5%. This means that for every 2000 women invited for screening throughout 10 years, one will have her life prolonged. In addition, 10 healthy women, who would not have been diagnosed if there had not been screening, will be diagnosed as breast cancer patients and will be treated unnecessarily. It is thus not clear whether screening does more good than harm. Women invited to screening should be fully informed of both benefits and harms.
Collapse
Affiliation(s)
- P C Gøtzsche
- The Nordic Cochrane Centre, Rigshospitalet, Dept. 7112, Blegdamsvej 9, Copenhagen Ø 2100 Denmark.
| | | |
Collapse
|
43
|
Chiu YH, Chen LS, Chan CC, Liou DM, Wu SC, Kuo HS, Chang HJ, Chen THH. Health information system for community-based multiple screening in Keelung, Taiwan (Keelung Community-based Integrated Screening No. 3). Int J Med Inform 2006; 75:369-83. [PMID: 16129660 DOI: 10.1016/j.ijmedinf.2005.07.033] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2004] [Revised: 07/12/2005] [Accepted: 07/13/2005] [Indexed: 11/28/2022]
Abstract
BACKGROUND Community-based multiple screening for common cancers and chronic diseases has increasingly gained attention. However, as infrastructure and evaluation system are more diversified and complicated compared with single screening, the development of a novel health information system is paramount. METHODS The main goal of our health information system was to support the multiple screening program not only from technical aspect but also from a broad range of perspectives including quality assurance system, organized features appertaining to screening, economic evaluation (cost-effectiveness or cost-utility analysis), epidemiological applications, behavior risk factor surveillance system, and social impact due to the introduction of the Keelung Community-Based Integrated Screening (KCIS) program. RESULTS Health information system was designed and programmed on the basis of the demand derived from KCIS within which five cancers and three chronic diseases were included. In addition to the detailed description of infrastructure and process, design, relevant database and security involved in health information system, an innovative and extensive evaluation system in accordance with the main goals was included in our health information system. CONCLUSION Our information system proposed several aspects regarding organized screening system that has never been addressed in computerized system supporting for single screening. These included quality assurance system, organization features, co-morbidity profiles, epidemiological applications and social and economic considerations.
Collapse
Affiliation(s)
- Yueh-Hsia Chiu
- Institute of Public Health and Institute of Health Informatics and Decision Making, National Yang-Ming University, Taipei, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
OBJECTIVES To review criteria for mass cancer screening among asymptomatic populations and barriers to secondary prevention of breast, cervical, and colorectal cancers. To describe challenges to implementing theoretically based interventions to increase appropriate cancer screening, follow-up, and surveillance. DATA SOURCES Published journal articles, text books, and epidemiologic reports. CONCLUSION Interventions to increase breast, cervical, and colorectal cancer screening participation must be approached from a systems perspective that includes patient, health care provider, and health care system variables. IMPLICATIONS FOR NURSING PRACTICE Understanding the array of factors that impede progress in the secondary prevention of cancer is necessary to improve care. Nurses have an important role in decreasing morbidity and mortality from breast, cervical, and colorectal cancers.
Collapse
|
45
|
Hofvind S, Skaane P, Vitak B, Wang H, Thoresen S, Eriksen L, Bjørndal H, Braaten A, Bjurstam N. Influence of Review Design on Percentages of Missed Interval Breast Cancers: Retrospective Study of Interval Cancers in a Population-based Screening Program. Radiology 2005; 237:437-43. [PMID: 16244251 DOI: 10.1148/radiol.2372041174] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To retrospectively investigate whether different review designs have an influence on the estimate of missed interval cancer in a population-based breast cancer screening program. MATERIALS AND METHODS The Norwegian Breast Cancer Screening Program invites women aged 50-69 years to undergo biennial screening mammography. The current study was part of the evaluation and scientific aspects of the screening program and thus was covered by the general ethical approval of the screening program as a part of the Cancer Registry of Norway. All participants signed an informed consent that specified that data related to their screening visit could be used for evaluation and scientific purposes. Six radiologists (9-34 years of experience in mammography) reviewed previously obtained bilateral two-view screening and diagnostic mammograms of 231 interval cancers, 117 screening-detected cancers, and 373 normal cases. Four review designs were used: individual and paired blinded review and individual and consensus informed review. A five-point interpretation scale was used to reclassify the cancers into missed cancers, minimal signs, and true cancers. The number and proportion of subgroups were estimated with 95% confidence intervals. RESULTS Of 231 interval cancers, 46 (19.9%) were reclassified as missed cancers with the mixed blinded individual review and 54 (23.4%) were classified as missed cancers with the mixed blinded paired review. Eighty-three cancers (35.9%) were classified as missed cancers with individual informed review, and 78 (33.8%) were classified as missed cancers with consensus informed review. Thirty-nine cancers (16.8%) were reclassified as missed when four or more radiologists assigned a score of 2 or more (probably benign or more suspicious); three cancers (1.3%) were reclassified as missed when a score of 4 or more (probably malignant or more suspicious) was assigned. CONCLUSION The percentage of interval cancers classified as missed ranged from 1.3% to 35.9% according to review design. To encourage learning, a review protocol should include both blinded and informed designs.
Collapse
|
46
|
Abstract
Strong evidence supports the value of breast cancer screening with mammography, and high-quality mammography screening can be considered a major public health achievement. As noted earlier in the discussion about the evaluation of service screening, the group of women who did not participate in mammographic screening in the decades after screening had been introduced had essentially unchanged or only minor improvements in mortality compared with the pattern before the introduction of screening, despite widespread use of adjuvant chemotherapy or hormonal therapy. Breast cancer should be treated in its preclinical phase if we are to save the lives of women with this disease, and a considerable body of evidence outlines best practices that, with broader adherence, would result in greater breast cancer mortality reductions than have been observed to date.
Collapse
Affiliation(s)
- Stephen W Duffy
- Cancer Research UK, Department of Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK
| | | | | | | | | | | |
Collapse
|
47
|
Castro F, Carter KJ, Kessler E, Erickson BA, Kseibi SA. The relation of breast cancer staging to screening protocol compliance: a computer simulation study. Comput Biol Med 2005; 35:91-101. [PMID: 15567180 DOI: 10.1016/j.compbiomed.2003.12.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2003] [Revised: 12/05/2003] [Accepted: 12/05/2003] [Indexed: 10/26/2022]
Abstract
A computer model based on relational database techniques was used to analyze the relationship between staging and population compliance to a breast cancer screening protocol. Stage distribution data permitted estimates of compliance to the protocol. This relationship followed the equation y=5.83e-2.44x where y was compliance and x was disease stage. Application of this equation to SEER and NCDB data estimated that the levels of compliance never exceeded 16 percent. Results indicated increasing clinical Stage IV disease as population compliance decreased. As the clinical staging increased there was increased sub-clinical Stage IV disease. With regular screening, simulation suggested that mortality would decrease.
Collapse
Affiliation(s)
- Frank Castro
- St. Elizabeth Health Center and The Northeastern Ohio Universities College of Medicine, Youngstown and Rootstown, OH, USA
| | | | | | | | | |
Collapse
|
48
|
Evans DGR, Lalloo F, Hopwood P, Maurice A, Baildam A, Brain A, Barr L, Howell A. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 2005; 31:1112-8. [PMID: 16005602 DOI: 10.1016/j.ejso.2005.05.007] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2005] [Revised: 05/12/2005] [Accepted: 05/18/2005] [Indexed: 11/15/2022] Open
Abstract
AIM To establish the uptake of contralateral risk reducing mastectomy in women informed of their risks and options at time of diagnosis of their primary unilateral breast cancer. METHODS We have assessed the surgical choices of 70 women diagnosed with breast cancer <50 years as part of a family history surveillance program and fully informed about their contralateral risks and surgical options. We have compared this to women from other surgical clinics who were subsequently found to harbour a pathogenic BRCA1/2 mutation. RESULTS Sixty-five percent (13/20) of BRCA1/2 mutation carriers and 59% (n=20/34) of those at the highest level of risk pre-diagnosis (33+% lifetime risk) opted for contra-lateral mastectomy in the study sample. In contrast only 10% (n=9/88) women identified as mutation carriers from other clinics opted for such surgery. CONCLUSIONS We would suggest that women with a significant family history and therefore a high contra-lateral breast cancer risk, should have these risks and management options discussed at the time of diagnosis of breast cancer.
Collapse
Affiliation(s)
- D G R Evans
- Academic Unit of Medical Genetics and Regional Genetics Service, St Mary's Hospital, Hathersage Road, Manchester, UK.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Sarkeala T, Hakama M, Saarenmaa I, Hakulinen T, Forsman H, Anttila A. Episode sensitivity in association with process indicators in the Finnish breast cancer screening program. Int J Cancer 2005; 118:174-9. [PMID: 16003756 DOI: 10.1002/ijc.21310] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We assessed the episode sensitivity of the Finnish mammography program for women aged 50-59 (partly 60-64) years and explored associations between the episode sensitivity and the screening process indicators from 1991 to 1999. For the study period, data were available from 10 screening centers. Records of 721,000 screening visits were linked to the files of the nationwide Finnish Cancer Registry from 1991 to 2001 at an individual level. The rates of screen-detected and interval breast cancers were calculated at the first and at the subsequent screens. The episode sensitivity was determined by contrasting the incidence of interval cancers with the expected population incidence rate without screening (incidence method) and as a proportion of interval cancers out of all cancers detected (detection method). At the subsequent screens, the episode sensitivity determined by the incidence method was 54% and by the detection method 65%. The sensitivity 0-11 and 12-23 months after the screening was 70% and 38%, respectively. The episode sensitivity decreased toward the end of the study period and increased with age. The center-specific sensitivity increased 13% per 1% absolute increase in the recall rate. In general, our study provides further information on the effectiveness of screening programs. The sensitivity estimates were comparable with those from other European service screening programs. The variability in the episode sensitivity suggests potential for variations in the future screening outcome.
Collapse
|
50
|
Abstract
It is the goal of the American Cancer Society to decrease the mortality from cancer by 50% and the incidence of cancer by 25% by the year 2015 in the United States. Achieving this goal requires intervention at the primary (incidence) and secondary (mortality) prevention stages, and will involve a concerted effort of the individual practitioner, governmental agencies, local, state, and national interest groups, and the population at large. Primary care practitioners must increase their level of enthusiasm for cancer prevention, and actively counsel patients about cancer risks and preventive measures. Practitioners should encourage inclined patients by providing support and specialty resources, such as dieticians, exercise therapists, and smoking and alcohol cessation programs. The greatest effort lies in the general population, who must adopt a healthier lifestyle, including appropriate diet, smoking cessation, control of obesity, and daily exercise. None of these lifestyle changes are easy to embrace, but once educated about lifestyle and risk of cancer, people have a powerful incentive to change. Continued public awareness campaigns and encouragement from health care providers are essential for the success of such programs. The success in smoking cessation shows that achieving societal lifestyle changes on a large scale is possible. The elderly are especially prone to benefit from primary and secondary prevention techniques, and it must not be assumed that only the young will realize the benefits of prevention and screening. The association of age and cancer risk will always be present, but need not be as consequential as it is now. Although cancer prevention may have a limited role in antiaging per se, the feasibility of cancer risk reduction has a definite role in aging successfully.
Collapse
Affiliation(s)
- Ramzi R Hajjar
- Department of Internal Medicine, Saint Louis University Health Sciences Center, MO 63104, USA.
| |
Collapse
|